Update on extended adjuvant therapy options in breast cancer.
This program looked at extended adjuvant therapy options in breast cancer, focusing on adjuvant therapies in women who are postmenopausal with advanced breast cancer and disease progression following traditional antiestrogen therapy. Aromatase inhibitors and novel approaches to managing hormone-dependent breast cancer were covered, as well as associated nursing implications.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000453:epidemiology / Q000628:therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D016903:Drug Monitoring / Q000451:nursing; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000453:epidemiology / Q000628:therapy*; D024802:Nurse's Role; D009730:Nursing Assessment / Q000379:methods; D009859:Oncology Nursing / Q000379:methods*; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen